Any 2026-2027 psychedelic approval will carry a mandatory REMS with certified-site and monitored-dosing requirements.

If a psychedelic gets approved as a medicine in 2026 or 2027, patients won't be able to pick it up at a regular pharmacy. Instead, they'll have to go to a specially approved clinic where trained staff supervise the experience. This exists because regulators want to make sure people are safe and fully understand what they're taking.

Dissociatives and hallucinogens demand supervised administration. The consent-readability findings reinforce that patient protection tooling isn't mature enough for open distribution.